glp-1 receptor agonists should be avoided in patients with are transforming diabetes care by improving blood sugar control, supporting weight loss, and reducing cardiovascular risk when used appropriately. Evidence-based therapy selection, correct dosing, and patient counseling are The GLP-1 Agonists and Obesity:
Description
LEADER Steering Committee on behalf of the LEADER Trial Investigators
After 38 weeks of age, mice were randomized within the three cohorts and equally distributed according to body composition
Qazi, S
doi: 10.1038/ijo.2015.172 17 DeaconCFHolstJJ
Safety of insulin analogs during pregnancy: a meta-analysis
